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Abstract
Cyclo-oxygenase-2 selective inhibitors are frequently used to
manage osteoarthritis. We compared the analgesic efficacy of
the novel cyclo-oxygenase-2 selective inhibitor lumiracoxib
(Prexige®) versus placebo and celecoxib in patients with knee
osteoarthritis. This seven day, double-blind, placebo and active
comparator controlled, parallel group study included 364
patients aged ≥50 years with moderate-to-severe symptomatic
knee osteoarthritis. Patients received lumiracoxib 400 mg/day
(four times the recommended chronic dose in osteoarthritis; n =
144), placebo (n = 75), or celecoxib 200 mg twice daily (n =
145). The primary variable was actual pain intensity difference
(100 mm visual–analogue scale) between baseline and the
mean of three hour and five hour assessments after the first
dose. Actual pain intensity difference, average and worst pain,
pain relief and functional status (Western Ontario and McMaster
Universities Osteoarthritis Index [WOMAC™]) were measured
over seven days. Patients also completed a global evaluation of
treatment effect at study end or premature discontinuation. For
the primary variable, the superiority of lumiracoxib versus
placebo, the noninferiority of lumiracoxib versus celecoxib, and
the superiority of lumiracoxib versus celecoxib were assessed
by closed test procedure adjusting for multiplicity, thereby
maintaining the overall 5% significance level. In addition,
celecoxib was assessed versus placebo in a predefined
exploratory manner to assess trial sensitivity. Lumiracoxib
provided better analgesia than placebo 3–5 hours after the first
dose (P  = 0.004) through to study end. The estimated
difference between lumiracoxib and celecoxib 3–5 hours after
the first dose was not significant (P = 0.185). Celecoxib was not
significantly different from placebo in this analysis (P = 0.069).
At study end 13.9% of lumiracoxib-treated patients reported
complete pain relief versus 5.5% and 5.3% of celecoxib and
placebo recipients, respectively. WOMAC™ total and subscales
improved for both active treatments versus placebo except for
difficulty in performing daily activities, for which celecoxib just
failed to achieve significance (P = 0.056). In the patient's global
evaluation of treatment effect, 58.1% of patients receiving
lumiracoxib rated treatment as 'excellent' or 'good', versus
48.6% of celecoxib and 25.3% of placebo patients. Lumiracoxib
was well tolerated. The overall incidence of adverse events was
similar across treatment groups.
ANCOVA = analysis of covariance; APID = actual pain intensity difference; AVPID = average pain intensity difference; CI = confidence interval; COX 
= cyclo-oxygenase; DPDA = difficulty in performing daily activities; ITT = intent to treat; MDP = minimal difference perceived; NSAID = nonsteroidal 
anti-inflammatory drug; OA = osteoarthritis; PID = pain intensity difference; SD = standard deviation; VAS = visual–analogue scale; WOMAC™ = 
Western Ontario and McMaster Osteoarthritis Index; WPID = worst pain intensity difference.Arthritis Research & Therapy    Vol 8 No 2    Wittenberg et al.
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Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely
regarded as the agents of choice when treating the chronic
pain of osteoarthritis (OA) [1-3]. This class of drugs prevents
prostaglandin synthesis by nonselectively inhibiting both iso-
forms of cyclo-oxygenase (COX) [4,5]; this profile also
accounts for their common side effects, including gastric irri-
tation, renal impairment and inhibition of platelet aggregation
[6-9]. NSAID use is associated with an increased risk for gas-
trointestinal ulcers and associated ulcer complications such
as bleeds and perforations [7]. COX-2 selective inhibitors
have demonstrated analgesic and anti-inflammatory efficacies
comparable with those of traditional NSAIDs in patients with
arthritis, combined with an improved safety profile [10-13].
Lumiracoxib (Prexige®, Novartis Pharma AG, Basel, Switzer-
land) is a novel COX-2 selective inhibitor in development for
the treatment of OA and acute pain. Selectivity for COX-2 over
COX-1 has been demonstrated for lumiracoxib both in vitro
and in vivo [14]. In addition, lumiracoxib is distinct from other
COX-2 selective inhibitors in that it lacks a sulphur-containing
moiety but rather possesses a carboxylic acid group, which
confers weakly acidic properties (pKa 4.7) [15]. The unique
molecular structure translates into a distinct pharmacokinetic
profile, such that lumiracoxib has a rapid plasma uptake (Tmax
2 hours) and a short mean plasma half-life of approximately 4
hours [16]. The pharmacokinetics of lumiracoxib are charac-
terized by good oral bioavailability [17], dose proportionality
with no accumulation, and no significant influence of age, sex,
or body weight on apparent plasma clearance [18]. In addition,
lumiracoxib has demonstrated sustained higher synovial fluid
concentrations compared with plasma concentrations in
patients with rheumatoid arthritis [19].
A four-week phase II study evaluated the efficacy of four doses
of lumiracoxib (50 mg twice daily, 100 mg twice daily, 200 mg
twice daily and 400 mg once daily) in patients with knee or hip
OA [20]. All doses reduced OA joint pain intensity, with signif-
icance over placebo observed after the first week of treatment.
Rapid onset of analgesia is necessary if patients are to accept
traditional NSAIDs or COX-2 selective inhibitor treatment,
because these patients often use their medication intermit-
tently on a pro re nata (when required) basis [21]. The present
study was conducted to evaluate the analgesic efficacy and
tolerability of lumiracoxib 400 mg once daily (four times the
recommended chronic dose in OA) and to compare them with
those of placebo and celecoxib 200 mg twice daily (recom-
mended dose in OA is 200 mg/day, administered as a single
dose or as 100 mg twice daily) [22] in patients with OA of the
knee over a 7-day period, with particular focus on the onset of
analgesia following the first dose.
Materials and methods
This was a randomized, double-blind, placebo and active com-
parator controlled, parallel group study conducted in 32 cen-
tres in Germany. All patients provided written informed
consent before study-related procedures were conducted,
and the study was performed in accordance with the princi-
ples of good clinical practice and the Declaration of Helsinki
(1964 and subsequent revisions). The study consisted of two
phases: a single-dose pain assessment phase and a multiple-
dose pain assessment phase.
Patients
Male or female patients aged 50 years or older with moderate-
to-severe symptomatic OA of the knee, according to the Amer-
ican College of Rheumatology criteria [23], were eligible for
inclusion. At screening, patients were required to be receiving
NSAIDs/simple analgesics for their OA and to have pain inten-
sity in the affected target joint of ≥40 mm on a 100 mm visual–
analogue scale (VAS) after activity (walking 20 paces on a flat
surface).
Exclusion criteria included secondary OA, concomitant signif-
icant medical problems, a history of gastrointestinal bleeding,
peptic ulceration or open knee surgery within one year of study
entry, and hypersensitivity to analgesics, antipyretics, NSAIDs,
or sulfonamides. Patients who had undergone observational
arthroscopy, arthroscopic surgery, or lavage within the pre-
ceding 180 days were not eligible for enrolment. Female
patients who were pregnant, lactating, or of childbearing age
and not using adequate means of contraception were
excluded.
Concomitant treatment with H2  receptor blockers, proton
pump inhibitors, misoprostol, methotrexate, warfarin, analge-
sics (other than rescue medication) and systemic corticoster-
oids was not permitted during the study; neither was
physiotherapy for the target joint. Patients who had received
intra-articular corticosteroids in the study joint during the three
months before the study were excluded. Patients receiving
chondroitin and/or glucosamine were excluded. Patients were
permitted to use rescue medication (acetaminophen ≤3 g/day)
during the study, although use of rescue medication was pro-
hibited from midnight before the baseline clinic visit.
Study design and treatments
After an initial screening visit patients entered a 2- to 7-day
washout period, during which any treatment with NSAIDs/
analgesics was discontinued (if applicable). Patients were
required to have VAS actual pain intensity at baseline of ≥50
mm for the most severely affected (target) knee joint after
activity. (The pain requirement at baseline following washout
[≥50 mm] was greater than at screening [≥40 mm]; thus, an
increase in pain from screening to baseline was required for
study entry.) Patients were subsequently randomly assigned
(in the ratio 2:2:1) to oral treatment with lumiracoxib 400 mgAvailable online http://arthritis-research.com/content/8/2/R35
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once daily, celecoxib 200 mg twice daily, or placebo. Blinding
was maintained by the double-dummy technique. Following 7
days of study medication, patients had a final clinic visit, during
which final pain assessments were made, pain records from
the patient diary were reviewed, and repeat functional status
and safety assessments were made. Each patient was con-
tacted by telephone for follow up approximately 14 days after
study completion.
Compliance was evaluated by quantifying the returned study
medication. Patients taking at least 80% of prescribed daily
medication were deemed compliant.
Efficacy assessments
In the single-dose pain assessment phase of the study, the
analgesic efficacy of a single dose of study medication was
evaluated. On the first day of treatment each patient rated
actual pain intensity (100 mm VAS, after activity) for the target
joint immediately before and at 3 and 5 hours after the first
dose of study medication. The primary efficacy variable was
pain intensity difference (PID) between the baseline pain
assessment and the mean of the 3-hour and 5-hour pain
assessments on the first day of treatment.
Secondary variables included evaluation of treatment over 7
days during the multiple-dose pain assessment phase.
Patients rated actual pain intensity, average pain intensity and
worst pain intensity using a 100 mm VAS after activity in the
morning and evening immediately before taking the next dose
of study medication. Actual pain intensity difference (APID),
average pain intensity difference (AVPID) and worst pain inten-
sity difference (WPID) from baseline were calculated. Pain
relief was recorded each evening (between 18:00 hours and
22:00 hours) and morning (30–60 minutes after getting up)
after taking the study medication using a 5-point categorical
scale (0 = none, 1 = little, 2 = moderate, 3 = a lot, 4 = com-
plete).
In order to evaluate the effect of study medication on usage of
rescue medication, all patients were requested to record the
date and time of rescue acetaminophen use after randomiza-
tion.
Functional status was assessed at baseline and study comple-
tion using the total and all three subscales of Western Ontario
and McMaster Universities Osteoarthritis Index (WOMAC™)
LK3.1 questionnaire (Likert scale) [24]: pain; stiffness; and dif-
ficulty in performing daily activities (DPDA).
At study end (or premature discontinuation), all patients com-
pleted a global evaluation of treatment effect, which was
recorded on a 4-point categorical scale (1 = poor, 2 = fair, 3
= good, 4 = excellent).
Safety and tolerability assessments
All adverse events reported by the patient or discovered by the
investigator during the study period were recorded and evalu-
ated in terms of seriousness, severity and potential relation-
ship to study medication. Safety assessments consisted of
routine laboratory tests (haematology, biochemistry and urinal-
Table 1
Patient demographics and baseline disease characteristics
Parameter/characteristic Lumiracoxib 400 mg once daily 
(n = 144)
Celecoxib 200 mg twice daily 
(n = 145)
Placebo 
(n = 75)
Age (years; mean ± SD) 64.7 ± 7.8 65.3 ± 9.5 64.8 ± 9.0
Males (n [%]) 66 (45.8) 54 (37.2) 33 (44.0)
Females (n [%]) 78 (54.2) 91 (62.8) 42 (56.0)
Disease duration (years; mean ± SD) 7.3 ± 6.7 7.5 ± 6.7 7.6 ± 8.6
VAS actuala pain intensity (mm; mean ± SD) 65.8 ± 11.5 64.1 ± 11.5 64.4 ± 12.4
VAS worstb pain intensity (mm; mean ± SD) 75.7 ± 11.5 75.5 ± 11.8 74.3 ± 11.2
VAS averagec pain intensity (mm; mean ± SD) 57.9 ± 12.5 56.9 ± 11.6 57.0 ± 14.8
WOMAC™ scores (mean ± SD)
Total 52.3 ± 12.6 53.9 ± 12.5 53.2 ± 11.6
Pain 10.6 ± 2.9 11.1 ± 2.9 10.8 ± 2.6
Stiffness 4.0 ± 1.7 4.0 ± 1.7 4.1 ± 1.3
DPDA 37.8 ± 9.2 38.8 ± 9.2 38.3 ± 8.7
aVAS actual pain intensity = mean of 3-hour and 5-hour assessments. bVAS worst pain intensity = worst pain intensity in the past 12 hours. cVAS 
average pain intensity = average pain intensity in the past 12 hours. DPDA, difficulty in performing daily activities; SD, standard deviation; VAS, 
visual–analogue scale; WOMAC™, Western Ontario and McMaster Universities Osteoarthritis Index.Arthritis Research & Therapy    Vol 8 No 2    Wittenberg et al.
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ysis), measurement of vital signs and 12-lead electrocardio-
gram recordings, which were completed at screening/
baseline and study end.
Statistical analysis
The primary efficacy variable was the APID between the base-
line pain assessment and the mean of the 3-hour and 5-hour
actual pain assessments after the first dose of study medica-
tion.
To maintain an overall 5% significance level, a closed-test pro-
cedure with a predefined sort order of the three hypothesis
tests (each at the 5% two-sided level) of the primary variable
was used [25]: superiority of lumiracoxib 400 mg once daily
versus placebo; noninferiority of lumiracoxib 400 mg once
daily versus celecoxib 200 mg twice daily; and superiority of
lumiracoxib 400 mg once daily versus celecoxib 200 mg twice
daily. In addition, in a prespecified, exploratory manner,
celecoxib was assessed versus placebo to examine the sensi-
tivity of the trial.
Use of sample sizes of 132 (lumiracoxib 400 mg once daily),
132 (celecoxib 200 mg twice daily) and 66 (placebo group)
resulted in powers of 94%, 98% and 80%, respectively, to
reject the three hypotheses in turn. The noninferiority margin of
lumiracoxib 400 mg once daily to celecoxib 200 mg twice daily
was predefined as 5 mm. An overall dropout rate of 10% and
a common standard deviation of 30 mm were assumed.
Analysis of efficacy was performed for all randomized patients
who had been exposed to study medication (intent-to-treat
population). All randomized patients were included in the
safety analysis.
PID was analysed using analysis of covariance (ANCOVA).
The statistical fixed-effects model considered treatment and
centre as main effects, whereas baseline actual pain was used
as a covariate. Data from small centres were pooled using a
predefined algorithm.
APID, AVPID and WPID were analyzed at each time point rel-
ative to baseline, using ANCOVA (as described above), and
pair-wise comparisons of treatment groups were calculated.
Pain relief was analyzed using a multiple logistic regression
model with treatment as an explanatory variable. The
WOMAC™ Total and subscale scores were analyzed using an
ANCOVA model, fitting scores at baseline, pooled centre and
treatment group. Finally, pair-wise comparisons of treatment
groups for the patient's global evaluation of treatment effect
were performed using a Cochran–Mantel–Haenszel test,
adjusting for pooled centre. All secondary variables were ana-
lyzed on the intent-to-treat population and all tests were two
sided, using a 5% level of significance.
Results
After screening 418 patients, a total of 364 were enrolled into
the study and received at least one dose of study medication
(lumiracoxib 400 mg once daily [n = 144], celecoxib 200 mg
twice daily [n = 145] and placebo [n = 75]). Five patients
(1.4%) withdrew from the study, four from the lumiracoxib
group (three due to adverse events and one for unsatisfactory
therapeutic effect) and one from the celecoxib group (due to
protocol violation).
Overall, the treatment groups were balanced for baseline
demographics and clinical characteristics (Table 1). Between
group differences in the distribution of female patients and
patients aged ≥75 years were not statistically significant (sex,
P = 0.3105; age, P = 0.8416) and were not considered to
have influenced the outcome of the study.
More than 90% of patients in each treatment group achieved
satisfactory compliance with prescribed medication during the
course of the study.
Efficacy
Single-dose pain assessment phase
The three main hypotheses of the primary efficacy variable
(APID between the baseline pain assessment and the mean of
the 3-hour and 5-hour actual pain assessments after the first
dose of study medication) were tested in sequence. First, lumi-
racoxib exhibited a statistically superior analgesic effect to that
of placebo, with an estimated treatment–placebo difference
(least square mean) of 5.8 mm (95% confidence interval [CI]
1.89–9.75 mm; P = 0.004; Table 2). Second, lumiracoxib was
confirmed to be noninferior to celecoxib in this analysis,
because the lower limit of the 95% CI for the difference
between lumiracoxib and celecoxib (lumiracoxib–celecoxib dif-
ference) was less than -5 mm. In the third hypothesis test, lumi-
racoxib was not significantly superior to celecoxib in terms of
Table 2
Mean actual PID for 3-hour and 5-hour time points after first dose
Mean actual PID (10 mm VAS) Lumiracoxib 400 mg (n = 144) Celecoxib 200 mg (n = 145) Placebo (n = 75)
Mean ± SD 19.8 ± 16.5** 16.8 ± 15.9† 13.4 ± 12.9
Median (range) 16.0 (-15.5, 74.5) 15.5 (-31.0, 58.5) 12.5 (-9.5, 48.5)
**P = 0.004, pair-wise comparison versus placebo using least square means; †P = 0.069, pair-wise comparison versus placebo using least 
square means. PID, pain intensity difference; SD, standard deviation; VAS, visual–analogue scale.Available online http://arthritis-research.com/content/8/2/R35
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the analgesic efficacy of the first dose (estimated least square
mean difference in favour of lumiracoxib: 2.2 mm, 95% CI -
1.06 to +5.45 mm; P = 0.185). Furthermore, celecoxib did not
have a statistically superior analgesic effect compared with
placebo (estimated treatment–placebo difference [least
square mean]: 3.6 mm, 95% CI -0.29 to +7.54 mm; P  =
0.069; Table 2).
As early as 3 hours after the dose on the first day, lumiracoxib
exhibited superior analgesic efficacy to that of placebo (esti-
mated treatment–placebo difference: 4.5 mm, 95% CI 0.44–
8.63 mm; P = 0.03). At the same time point, the percentages
of patients who assessed their pain relief as either 'a lot' or
'complete' relative to baseline were 12.5%, 5.5% and 9.3% in
the lumiracoxib, celecoxib and placebo groups, respectively.
Corresponding values 5 hours after the dose were 11.1%,
10.3% and 8.0%, respectively.
Multiple-dose pain assessment phase
For the second assessment phase (multiple dosing over 7
days), lumiracoxib was statistically superior to placebo at all
time points and celecoxib was superior to placebo at most
time points (Figure 1). Lumiracoxib was numerically superior to
celecoxib throughout the study, but this achieved statistical
significance only in the evening assessment of the first day of
treatment (P  = 0.022). Although not tested statistically,
celecoxib-treated patients appeared to have somewhat less
pain relief at the evening assessments compared with morning
assessments. At study end, the estimated differences for APID
relative to placebo were statistically significant for both lumira-
coxib (10.7 mm, 95% CI 4.70–16.7 mm; P = 0.001) and
celecoxib (8.7 mm, 95% CI 2.68–14.66 mm; P  = 0.005).
However, no significant difference was apparent between the
active treatment groups at study end (estimated difference for
lumiracoxib versus celecoxib in APID: 2.0 mm, 95% CI -2.94
to +7.01 mm; P = 0.421).
At study end, 13.9% of patients receiving lumiracoxib experi-
enced 'complete' pain relief at study end compared with 5.5%
of patients receiving celecoxib and 5.3% of patients receiving
placebo. Furthermore, the percentages of patients who
assessed their pain relief as 'a lot' were 34.7%, 30.3% and
22.7% in the lumiracoxib, celecoxib and placebo groups,
respectively. With respect to pain relief, lumiracoxib was sig-
nificantly superior to placebo (P = 0.001) whereas celecoxib
just failed to achieve significance (P = 0.051). There was no
significant difference between the active treatment groups at
study end (P = 0.076).
The majority of patients (87% of lumiracoxib-treated patients,
82% of celecoxib-treated patients and 84% of placebo-
treated patients) did not require rescue acetaminophen during
the study.
Table 3
Change from baseline and treatment differences in WOMAC™ total and subscale scores at study end
WOMAC™ total score WOMAC™ pain 
subscale score
WOMAC™ DPDA 
subscale scorea
WOMAC™ stiffness 
subscale score
Change from baseline at study end (mean ± SD)
Lumiracoxib 400 mg daily (n = 144) -21.3 ± 19.9 -4.4 ± 4.4 -15.4 ± 14.6 -1.5 ± 1.9
Celecoxib 200 mg twice daily (n = 145) -17.6 ± 14.2 -4.0 ± 3.3 -12.3 ± 10.5 -1.3 ± 1.8
Placebo (n = 75) -12.5 ± 13.4 -2.7 ± 3.2 -9.0 ± 9.8 -0.8 ± 1.5
Estimated treatment differences at study end (least square means [95% CI])
Lumiracoxib versus placebo -8.9 (-13.30 to -4.56)*** -1.8 (-2.77 to -0.83)*** -6.4 (-9.62 to -3.23)*** -0.7 (-1.14 to -0.31)***
Celecoxib versus placebo -4.8 (-9.15 to -0.44)* -1.1 (-2.02 to -0.10)* -3.1(-6.30 to +0.07) -0.6 (-1.00 to -0.18)**
Lumiracoxib versus celecoxib -4.1 (-7.76 to -0.51)* -0.7 (-1.54 to +0.06) -3.3 (-5.96 to -0.66)* -0.1 (-0.47 to +0.21)
aData missing for one patient in each of the lumiracoxib and celecoxib treatment groups. *P < 0.05, **P < 0.01, ***P = 0.001. CI, confidence 
interval; DPDA, difficulty in performing daily activities; SD, standard deviation; WOMAC™ = Western Ontario and McMaster Universities 
Osteoarthritis Index.
Figure 1
Mean actual pain intensity difference during seven days of treatment Mean actual pain intensity difference during seven days of treatment.Arthritis Research & Therapy    Vol 8 No 2    Wittenberg et al.
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Overall, both active treatment groups were characterized by
significantly improved WOMAC™ total scores compared with
placebo at study end (Table 3). In addition, lumiracoxib was
significantly superior to celecoxib (P = 0.026) with regard to
the WOMAC™ total score. Lumiracoxib was superior to both
celecoxib (P = 0.015) and placebo (P < 0.001) with regard to
the DPDA subscale score, with the difference between the
celecoxib and placebo groups just failing to achieve signifi-
cance (P  = 0.056). Mean changes from baseline in
WOMAC™ total and subscale scores are also shown in Table
3.
In terms of patient's global evaluation of treatment effect, sub-
stantially more patients in the lumiracoxib group (58.1%)
assessed treatment effect as either 'excellent' or 'good' at
study end compared with 48.6% of celecoxib-treated patients
and 25.3% of placebo-treated patients (Figure 2). For both
active treatments, a highly significant difference relative to pla-
cebo was apparent (lumiracoxib, P < 0.001; celecoxib, P =
0.001); however, there was no difference between active
treatment groups (P = 0.100).
Safety and tolerability
Only one serious adverse event was reported (silent myocar-
dial infarction in a celecoxib-treated patient). This event was
suspected to be related to the study drug but it did not lead to
premature discontinuation because it was detected on elec-
trocardiogram recordings on the final study day. Three
patients (2.1%) in the lumiracoxib group were prematurely
withdrawn from the study because of adverse events, which
included moderate bronchitis and mild nasopharyngitis in one
patient each (both were considered to be unrelated to study
drug). A further patient was withdrawn because of severe
upper abdominal pain that was considered by the investigator
to be related to study drug. Of note, this patient had previously
(six months before study entry) experienced an episode of
abdominal pain during short-term therapy with celecoxib.
Overall, a comparable and low proportion of patients in each
treatment group reported at least one adverse event during the
study: 14.6% in the lumiracoxib group, 11.0% in the celecoxib
group, and 13.3% in the placebo group. Gastrointestinal dis-
orders were the most frequent adverse events, occurring with
greater frequency in both active treatment groups than with
placebo. The majority of adverse events in each treatment
group were of mild severity. Moderate adverse events were
infrequent and were not associated with a specific body sys-
tem.
Adverse events assessed by the investigator as being possibly
study drug related occurred in 6.3%, 6.2% and 8.0% of
patients in the lumiracoxib, celecoxib and placebo groups,
respectively. Overall, adverse events affecting the gastrointes-
tinal system were most frequently reported as being possibly
study drug related (4.2%, 4.8% and 2.7% of patients in the
lumiracoxib, celecoxib and placebo groups, respectively).
There were no relevant changes in vital signs or electrocardi-
ographic variables between baseline and study end in any of
the treatment groups.
Discussion
This short-term study established that lumiracoxib, a novel
COX-2 selective inhibitor, provides rapid and effective analge-
sia in patients with OA of the knee. The primary efficacy varia-
ble (mean PID 3–5 hours after dose) was similar to those used
in other single-dose studies of COX-2 selective inhibitors in
acute pain [26] or in patients with OA flare [27]. Celecoxib
was chosen as the active comparator because of its estab-
lished analgesic efficacy in patients with OA of the knee
[28,29].
Previous studies have shown that lumiracoxib provides signifi-
cant pain relief over 13 weeks of treatment in patients with OA
compared with placebo [30,31]. In the present study we found
that the first dose of lumiracoxib 400 mg decreased OA pain
intensity (100 mm VAS) 3–5 hours after dose by 19.8 mm (P
= 0.004, versus placebo) compared with a mean decrease of
16.8 mm (P = 0.069, versus placebo) with celecoxib 200 mg
and 13.4 mm with placebo. Lumiracoxib was noninferior but
not significantly superior to celecoxib in this analysis 3–5
hours after dose. These findings are consistent with earlier
pharmacodynamic studies with lumiracoxib, which found the
difference from baseline in mean VAS scores at 4 hours after
dosing to be >20 mm with lumiracoxib 400 mg compared with
<5 mm in placebo-treated patients [32]. The results reported
here are similar to findings with other COX-2 selective inhibi-
tors, where the speed of onset of analgesia was studied in an
OA population meeting OA flare criteria [27]. At 3 hours after
the dose, the mean decrease in OA pain intensity (100 mm
VAS) was 21.7 mm with valdecoxib 10 mg and 19.8 mm with
rofecoxib 25 mg, as compared with 15.5 mm with placebo (P
< 0.01). In addition, it has been reported that a 30–33%
decrease in VAS pain scores represents a clinically meaning-
Figure 2
Patient's global evaluation of treatment effect at study end Patient's global evaluation of treatment effect at study end.Available online http://arthritis-research.com/content/8/2/R35
Page 7 of 9
(page number not for citation purposes)
ful change in either acute or chronic pain [33,34]. For lumira-
coxib 400 mg, a 30% decrease from actual pain at baseline
was observed at the 3–5 hour post-dose assessment, sug-
gesting that this change in pain intensity was clinically rele-
vant.
The primary objective of the study was to examine the single-
dose onset of analgesia with lumiracoxib. As such, a dose of
lumiracoxib appropriate for acute use (400 mg) was used. Pre-
vious studies with this dose of lumiracoxib in acute pain have
shown that it provides rapid and effective analgesia [35-37].
The recommended chronic dose of lumiracoxib is 100 mg
daily. In order for the active comparison to be relevant, a dose
of celecoxib considered to be appropriate for acute pain was
chosen (200 mg twice daily) [22]. (The recommended dose of
celecoxib in OA is 200 mg daily, administered as a single dose
or as 100 mg twice daily [22].)
Both lumiracoxib and celecoxib had statistically significant effi-
cacy compared with placebo in terms of secondary efficacy
variables assessed during the multiple-dose assessment
period, including APID, AVPID, WPID and extent of pain relief.
The significant treatment–placebo differences in actual pain
intensity (100 mm VAS) at study end (10.7 mm for lumiracoxib
400 mg once daily, P = 0.001; 8.7 mm for celecoxib 200 mg
twice daily, P = 0.005) were comparable with those previously
reported after 13 weeks of treatment (8.8 mm for lumiracoxib
400 mg once daily; 6.3 mm for celecoxib 200 mg once daily)
[31]. At study end, no significant differences were observed
between active treatments in terms of APID. Substantially
more patients in the lumiracoxib group assessed treatment
effect as 'excellent' or 'good' at study end compared with
those who received celecoxib (58% and 49%, respectively).
Interestingly, only around 25% of placebo recipients rated
treatment as 'poor' at the end of the study, despite a progres-
sive increase in APID during treatment. This 'placebo effect' is
not unique to the treatment of patients with joint disorders [38]
and is perhaps attributable to psychological mechanisms such
as an awareness of being closely observed and active compli-
ance with the presumed wishes of researchers. It is notable,
however, that against this background lumiracoxib maintained
significant superiority in terms of analgesic efficacy.
Patients received celecoxib 200 mg in the morning and
evening, whereas lumiracoxib was given in the morning only,
with a lumiracoxib-matched placebo administered in the
evening. The multiple-dose actual PID scores for lumiracoxib
over the 7-day treatment period show that the analgesic effect
of lumiracoxib is maintained over a 24-hour period and there-
fore supports once-daily administration.
Evaluation of WOMAC™ subscales in the study allowed
assessment of the effect of treatment on aspects of patients'
daily lives relating to their condition, including pain, stiffness
and the ability to perform daily activities. Overall, both lumira-
coxib and celecoxib were associated with significantly lower
pain and stiffness WOMAC™ subscale scores than placebo at
study end. This is of particular significance for patients with
knee OA, whose mobility and quality of life can be severely
impaired [39]. Treatment–placebo differences in the
WOMAC™ total score at 7 days (8.9 for lumiracoxib 400 mg
once daily; 4.8 for celecoxib 200 mg twice daily) were compa-
rable with those seen in longer 13-week studies with lumira-
coxib and celecoxib (7.5 for lumiracoxib 400 mg once daily;
6.0 for celecoxib 200 mg once daily) [31]. It has been sug-
gested that the minimal difference perceived (MDP) clinically
from baseline in WOMAC™ DPDA score should be the mini-
mal difference that is perceived by 75% of patients (MDP75),
and a recent study of 1354 patients reported the MDP75 for
the WOMAC™ DPDA subscale to be 5.2 [40]. In this study,
the change from baseline in the DPDA subscale score was
15.4 for lumiracoxib 400 mg once daily compared with 12.3
for celecoxib 200 mg twice daily. This suggests that lumira-
coxib provided clinically meaningful improvements in the ability
of patients to perform daily activities during this 7-day study.
Lumiracoxib was well tolerated in this short study. The inci-
dence of adverse events was comparable between all three
groups. Previous studies of lumiracoxib tolerability over 13
weeks of treatment have found that lumiracoxib 200 mg or
400 mg daily has gastrointestinal tolerability that is superior to
that of traditional NSAIDs including diclofenac, ibuprofen and
naproxen [41].
Conclusion
Lumiracoxib 400 mg (four times the recommended chronic
dose in OA) had a rapid onset of action in patients with OA of
the knee, with an analgesic effect significantly superior to that
of placebo that was demonstrated as early as three hours fol-
lowing the first dose. In addition, analgesia was maintained
throughout the dosing interval; lumiracoxib was superior to
placebo for overall pain relief at both morning and evening
assessments throughout the study. The rapid onset of analge-
sia represents a useful attribute in the management of patients
with OA, who are likely to require intermittent pro re nata med-
ication.
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